• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • İktisadi ve İdari Bilimler Fakültesi
  • Sağlık İdaresi Bölümü
  • Sağlık İdaresi Bölümü Makale Koleksiyonu
  • View Item
  •   DSpace Home
  • İktisadi ve İdari Bilimler Fakültesi
  • Sağlık İdaresi Bölümü
  • Sağlık İdaresi Bölümü Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cost-Effectiveness Analysis Of Pemetrexed And Gemcitabine Treatment For Advanced Nonsmall Cell Lung Cancer In Turkey

View/Open
licence.txt (265bytes)
sag-46-1-25-1408-4.pdf (86.93Kb)
Date
2016
Author
Balcik, Pinar Yalcin
Sahin, Bayram
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
Background/aim: The purpose of the study is to determine the cost-effectiveness of the chemotherapy medications that contain gemcitabine and pemetrexed, which are used in the treatment of advanced nonsmall cell lung cancer (NSCLC). Materials and methods: The study evaluated the effectiveness and cost of platinum-based pemetrexed and gemcitabine treatments as the first-line treatment of advanced NSCLC with the use of the Markov model, and from the perspective of the Social Security Institution. NSCLC costs calculated on the basis of experts' opinions and the effectiveness values calculated by administering the EQ-5D questionnaire to the patients were analyzed. All direct medical costs were included in the model. Results: While the life-long cost of gemcitabine/cisplatin treatment was determined to be 10,347.45 Turkish lira per patient, it was determined as 17,783.34 for pemetrexed/cisplatin treatment. The incremental cost of pemetrexed/cisplatin treatment is 220,754 per quality-adjusted life year. Conclusion: Although there is no official threshold value in Turkey, due to the fact that the incremental cost effectiveness ratio exceeds the threshold value calculated on the basis of GDP per capita, it is understood that pemetrexed/cisplatin is not cost-effective in the first-line treatment of advanced NSCLC.
URI
https://doi.org/10.3906/sag-1408-4
http://hdl.handle.net/11655/21336
xmlui.mirage2.itemSummaryView.Collections
  • Sağlık İdaresi Bölümü Makale Koleksiyonu [24]
Hacettepe Üniversitesi Kütüphaneleri
Açık Erişim Birimi
Beytepe Kütüphanesi | Tel: (90 - 312) 297 6585-117 || Sağlık Bilimleri Kütüphanesi | Tel: (90 - 312) 305 1067
Bizi Takip Edebilirsiniz: Facebook | Twitter | Youtube | Instagram
Web sayfası:www.library.hacettepe.edu.tr | E-posta:openaccess@hacettepe.edu.tr
Sayfanın çıktısını almak için lütfen tıklayınız.
Contact Us | Send Feedback



DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV
 

 


DSpace@Hacettepe
huk openaire onayı
by OpenAIRE

About HUAES
Open Access PolicyGuidesSubcriptionsContact

livechat

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsIndexing SourceFundingxmlui.ArtifactBrowser.Navigation.browse_subtypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsIndexing SourceFundingxmlui.ArtifactBrowser.Navigation.browse_subtype

My Account

LoginRegister

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV